Single peptides and combination modalities for triple negative breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Single peptides and combination modalities for triple negative breast cancer

Published:2019-10-22 Issue:5 Volume:235 Page:4089-4108
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J Cell Physiol

Author:

Razazan Atefeh¹²,Behravan Javad¹³⁴^ORCID

Affiliation:

1. Biotechnology Research Center, Pharmaceutical Technology Institute Mashhad University of Medical Sciences Mashhad Iran

2. Center for Obesity, Diabetes and Metabolism (Internal Medicine‐Molecular Medicine) Wake Forest School of Medicine Winston‐Salem North Carolina

3. School of Pharmacy University of Waterloo Waterloo Canada

4. Theraphage Inc., Kitchener Ontario Canada

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcp.29300

Reference153 articles.

1. MUC1 as a target antigen for cancer immunotherapy

2. Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).

3. NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer

4. Blockade of MMP14 Activity in Murine Breast Carcinomas: Implications for Macrophages, Vessels, and Radiotherapy

5. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ellagic Acid-Gold Nanoparticle Complex as Anticancer Agent in Triple-Negative Breast Cancer Cells;Nano LIFE;2024-03-06

2. Recent advances in targeted strategies for triple-negative breast cancer;Journal of Hematology & Oncology;2023-08-28

3. Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer;Frontiers in Immunology;2023-08-25

4. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer;Frontiers in Immunology;2022-11-02

5. Narrative review of progress in pathological diagnosis of breast cancer;Translational Breast Cancer Research;2022-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3